Ketamine and other potential glutamate antidepressants

Psychiatry Research

Volumn 225, Issue 1-2, 2015, Pages 1-13

  Dutta, Arpan ^a   McKie, Shane ^a   Deakin, J F William ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Glutamate; Ketamine; Major depressive disorder; N methyl d aspartate; Amino 3 hydroxy 5 methyl 4 isoxazolepropionic acid

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMANTADINE; ANESTHETIC AGENT; ANTIDEPRESSANT AGENT; AZD 2066; BASIMGLURANT; COLURACETAM; DOPAMINE; GLUTAMIC ACID; KETAMINE; LAMOTRIGINE; MAMMALIAN TARGET OF RAPAMYCIN; MEMANTINE; METABOTROPIC RECEPTOR; MK 0657; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PAROXETINE; PLACEBO; RAPASTINEL; RILUZOLE; SEROTONIN UPTAKE INHIBITOR; TRAXOPRODIL; UNCLASSIFIED DRUG; AMPA RECEPTOR;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTERIOR CINGULATE; BIPOLAR DEPRESSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; HAMILTON SCALE; HUMAN; MAGNETOENCEPHALOGRAPHY; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; SINGLE DRUG DOSE; SOMATOSENSORY CORTEX; SYMPTOMATOLOGY; TREATMENT RESPONSE; WORKING MEMORY; ANIMAL; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; METABOLISM; TREATMENT OUTCOME;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; GLUTAMIC ACID; HUMANS; KETAMINE; MEMANTINE; RECEPTORS, AMPA; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; TREATMENT OUTCOME;

EID: 84916618771     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.10.028     Document Type: Review

References (149)

1. aan het Rot M., Collins K.A., Murrough J.W., Perez A.M., Reich D.L., Charney D.S., Mathew S.J. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biological Psychiatry 2010, 67:139-145.
2. Abdallah C.G., Fasula M., Kelmendi B., Sanacora G., Ostroff R. Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. Journal of ECT 2012, 28:157-161.
3. Abdallah C.G., Jiang L., De Feyter H.M., Fasula M., Krystal J.H., Rothman D.L., Mason G.F., Sanacora G. Glutamate Metabolism in Major Depressive Disorder. American Journal of Psychiatry 2014, [Epub ahead of print]. 10.1176/appi.ajp.2014.14010067.
4. Amann B., Born C., Crespo J.M., Pomarol-Clotet E., McKenna P. Lamotrigine: when and where does it act in affective disorders? A systematic review. Journal of Psychopharmacology 2011, 25:1289-1294.
5. Ampuero E., Rubio F.J., Falcon R., Sandoval M., Diaz-Veliz G., Gonzalez R.E., Earle N., Dagnino-Subiabre A., Aboitiz F., Orrego F., Wyneken U. Chronic fluoxetine treatment induces structural plasticity and selective changes in glutamate receptor subunits in the rat cerebral cortex. Neuroscience 2010, 169:98-108.
6. Anand A., Charney D.S., Oren D.A., Berman R.M., Hu S., Cappiello A., Krystal J.H. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine. Archives of General Psychiatry 2000, 57:270-276.
7. Beneyto M., Kristiansen L.V., Oni-Orisan A., McCullumsmith R.E., Meador-Woodruff J.H. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007, 32:1888-1902.
8. Benoit E., Escande D. Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre. European Journal of Physiology 1991, 419:603-609.
9. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., Krystal J.H. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 2000, 47:351-354.
10. Bhagwagar Z., Wylezinska M., Jezzard P., Evans J., Boorman E., Matthews P.M., Cowen P.J. Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. International Journal of Neuropsychopharmacology 2008, 11:255-260.
11. Blanpied T.A., Clarke R.J., Johnson J.W. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. Journal of Neuroscience 2005, 25:3312-3322.
12. Block W., Traber F., von Widdern O., Metten M., Schild H., Maier W., Zobel A., Jessen F. Proton MR spectroscopy of the hippocampus at 3T in patients with unipolar major depressive disorder: correlates and predictors of treatment response. International Journal of Neuropsychopharmacology 2009, 12.
13. Boyce-Rustay J.M., Holmes A. Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice. Neuropsychopharmacology 2006, 31:2405-2414.
14. Boyer P.A., Skolnick P., Fossom L.H. Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. Journal of Molecular Neuroscience 1998, 10:219-233.
15. Brennan B.P., Hudson J.I., Jensen J.E., McCarthy J., Roberts J.L., Prescot A.P., Cohen B.M., Pope H.G., Renshaw P.F., Ongur D. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology 2010, 35:834-846.
16. Burch, R.M., 2012. A phase 2, randomized, double blind, single intravenous dose study of GLYX-13, an NMDA receptor glycine site functional partial agonist, in subjects with Major Depressive Disorder with inadequate response to antidepressant medication. In: Proceedings of the ACNP 51st Annual Meeting, Hollywood, December 2012.
17. Calabrese J.R., Bowden C.L., Sachs G.S., Ascher J.A., Monaghan E., Rudd G.D. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. Journal of Clinical Psychiatry 1999, 60:79-88.
18. Carlson P.J., Diazgranados N., Nugent A.C., Ibrahim L., Luckenbaugh D.A., Brutsche N., Herscovitch P., Manji H.K., Zarate C.A., Drevets W.C. Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biological Psychiatry 2013, 73:1213-1221.
19. Chilukuri H., Reddy N.P., Pathapati R.M., Manu A.N., Jollu S., Shaik A.B. Acute antidepressant effects of intramuscular versus intravenous ketamine. Indian Journal of Psychological Medicine 2014, 36:71-76.
20. Choudhary P.V., Molnar M., Evans S.J., Tomita H., Li J.Z., Vawter M.P., Myers R.M., Bunney W.E., Akil H., Watson S.J., Jones E.G. Altered cortical glutamatergic and GABAergic signal transmission and glial involvement in depression. Proceedings of the National Academy of Sciences 2005, 102:15653-15658.
21. Chourbaji S., Vogt M.A., Fumagalli F., Sohr R., Frasca A., Brandwein C., Hortnagl H., Riva M.A., Sprengel R., Gass P. AMPA receptor subunit 1 (GluR-A) knockout mice model the glutamate hypothesis of depression. FASEB Journal 2008, 22:3129-3134.
22. Cornwell B.R., Salvadore G., Furey M., Marquardt C.A., Brutsche N.E., Grillon C., Zarate C.A. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biological Psychiatry 2012, 72:555-561.
23. Correll G.E., Futter G.E. Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions. Pain Medicine 2006, 7:92-95.
24. De Vry J., Jentzsch K.R. Role of the NMDA receptor NR2B subunit in the discriminative stimulus effects of ketamine. Behavioural Pharmacology 2003, 14:229-235.
25. Deakin J.F.W., Lees J., McKie S., Hallak J.E.C., Williams S.R., Dursun S.M. Glutamate and the neural basis of the subjective effects of ketamine. Archives of General Psychiatry 2008, 65:154-164.
26. Denk M.C., Rewerts C., Holsboer F., Erhardt-Lehmann A., Turck C.W. Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation. American Journal of Psychiatry 2011, 168:751-752.
27. Diazgranados N., Ibrahim L.A., Brutsche N.E., Ameli R., Henter I.D., Luckenbaugh D.A., Machado-Vieira R., Zarate C.A. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-d-aspartate antagonist in patients with treatment-resistant major depressive disorder. Journal of Clinical Psychiatry 2010, 71:1605-1611.
28. Diazgranados N., Ibrahim L.A., Brutsche N.E., Newberg A., Kronstein P., Khalife S., Kammerer W.A., Quezado Z., Luckenbaugh D.A., Salvadore G., Machado-Vieira R., Manji H.K., Zarate C.A. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Archives of General Psychiatry 2010, 67:793-802.
29. Dietrich D.E., Bode L., Spannhuth C.W., Lau T., Huber T.J., Brodhun B., Ludwig H., Emrich H.M. Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial. Bipolar Disorders 2000, 2:65-70.
30. Du J., Suzuki K., Wei K., Wang Y., Blumenthal R., Chen Z., Falke C., Zarate C.A., Manji H.K. The anticonvulsants lamotrigine, riluzole and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 2007, 32:793-802.
31. Duncan W.C., Selter J., Brutsche N., Sarasso S., Zarate C.A. Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder. Journal of Affective Disorders 2013, 145:115-119.
32. Duncan W.C., Sarasso S., Ferrarelli F., Selter J., Riedner B.A., Hejazi N.S., Yuan P., Brutsche N., Manji H.K., Tononi G., Zarate C.A. Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. International Journal of Neuropsychopharmacology 2013, 16:301-311.
33. Ferguson J.M., Shingleton R.N. An open-label, flexible dose study of memantine in major depressive disorder. Clinical Neuropharmacology 2007, 30:136-144.
34. Feyissa A.M., Chandran A., Stockmeier C.A., Karolewicz B. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2009, 33:70-75.
35. Feyissa A.M., Woolverton W.L., Miguel-Hidalgo J.J., Wang Z., Kyle P.B., Hasler G., Stockmeier C.A., Iyo A.H., Karolewicz B. Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2010, 34:279-283.
36. Flint J., Kendler K.S. The genetics of major depression. Neuron 2014, 81:484-503.
37. Fukumoto K., Iijima M., Chaki S. Serotonin-1A receptor stimulation mediates effects of a metabotropic glutamate 2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and an N-methyl-d-aspartate receptor antagonist, ketamine, in the novelty-suppressed feeding test. Psychopharmacology 2014, 231:2291-2298.
38. Geddes J.R., Calabrese J.R., Goodwin G.M. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. British Journal of Psychiatry 2009, 194:4-9.
39. Ghasemi M., Kazemi M.H., Yoosefi A., Ghasemi A., Paragomi P., Amini H., Afzali M.H. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Research 2014, 215:355-361.
40. Glue P., Gulati A., Le Nedelec M., Duffull S. Dose- and exposure-response to ketamine in depression. Biological Psychiatry 2011, 70:e9-e10. (author reply e11-e12).
41. Goforth H.W., Holsinger T. Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy. Journal of ECT 2007, 23:23-25.
42. Grunze H., von Wegerer J., Greene R.W., Walden J. Modulation of calcium and potassium currents by lamotrigine. Neuropsychobiology 1998, 38:131-138.
43. Haile C.N., Murrough J.W., Iosifescu D.V., Chang L.C., Al Jurdi R.K., Foulkes A., Iqbal S., Mahoney J.J., De La Garza R., Charney D.S., Newton T.F., Mathew S.J. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. International Journal of Neuropsychopharmacology 2014, 17:331-336.
44. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Research Reviews 2009, 61:105-123.
45. Hashimoto K., Malchow B., Falkai P., Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. European Archives of Psychiatry and Clinical Neuroscience 2013, 263:367-377.
46. Hasler G., van der Veen J.W., Tumonis T., Meyers N., Shen J., Drevets W.C. Reduced prefrontal glutamate/glutamine and γ-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Archives of General Psychiatry 2007, 64:193-200.
47. Hirota K., Lambert D.G. Ketamine: its mechanism(s) of action and unusual clinical uses. British Journal of Anaesthesia 1996, 77:441-444.
48. Hirota K., Okawa H., Appadu B.L., Grandy D.K., Devi L.A., Lambert D.G. Stereoselective interaction of ketamine with recombinant μ, κ and δ opiod receptors expressed in chinese hamster ovary cells. Anesthesiology 1999, 90:174-182.
49. Huettner J.E., Bean B.P. Block of N-methyl-d-aspartate-activated current by the anticonvulsant MK-801: selective binding to open channels. Proceedings of the National Academy of Sciences of the United States of America 1988, 85:1307-1311.
50. Ibrahim L., Diaz Granados N., Jolkovsky L., Brutsche N., Luckenbaugh D.A., Herring W.J., Potter W.Z., Zarate C.A. A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. Journal of Clinical Psychopharmacology 2012, 32:551-557.
51. Ibrahim L., Diazgranados N., Franco-Chaves J., Brutsche N., Henter I.D., Kronstein P., Moaddel R., Wainer I., Luckenbaugh D.A., Manji H.K., Zarate C.A. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 2012, 37:1526-1533.
52. Ibrahim L., Diazgranados N., Luckenbaugh D.A., Machado-Vieira R., Baumann J., Mallinger A.G., Zarate C.A. Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2011, 35:1155-1159.
53. Irwin S.A., Iglewicz A. Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. Journal of Palliative Medicine 2010, 13:903-908.
54. Jarventausta K., Chrapek W., Kampman O., Tuohimaa K., Bjorkqvist M., Hakkinen H., Yli-Hankala A., Leinonen E. Effects of S-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study. Journal of ECT 2013, 29:158-161.
55. Kalia L.V., Kalia S.K., Salter M.W. NMDA receptors in clinical neurology: excitatory times ahead. Neurology 2008, 7:742-755.
56. Karolewicz B., Feyissa A.M., Chandran A., Legutko B., Ordway G.A., Rajkowska G., Stockmeier C. Glutamate receptors expression in postmortem brain from depressed patients. Biological Psychiatry 2009, 65(Suppl.):177S.
57. Kegeles L.S., Martinez D., Kochan L.D., Hwang D.-R., Huang Y., Mawlawi O., Suckow R.F., van Heertum R.L., Laruelle M. NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans. Synapse 2002, 43:19-29.
58. Kohrs R., Durieux M.E. Ketamine: teaching an old drug new tricks. Anesthesia and Analgesia 1998, 87:1186-1193.
59. Kranaster L., Kammerer-Ciernioch J., Hoyer C., Sartorius A. Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study. European Archives of Psychiatry and Clinical Neuroscience 2011, 261:575-582.
60. Kudoh A., Takahira Y., Katagai H., Takazawa T. Small-dose ketamine improves the postoperative state of depressed patients. Anesthesia and Analgesia 2002, 95:114-118.
61. Kurita M., Nishino S., Kato M., Numata Y., Sato T. Plasma brain-derived neurotrophic factor levels predict the clinical outcome of depression treatment in a naturalistic study. PLoS One 2012, 7:e39212.
62. Laje G., Lally N., Mathews D., Brutsche N., Chemerinski A., Akula N., Kelmendi B., Simen A., McMahon F.J., Sanacora G., Zarate C. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biological Psychiatry 2012, 72:e27-e28.
63. Lapidus K.A., Levitch C.F., Perez A.M., Brallier J.W., Parides M.K., Soleimani L., Feder A., Iosifescu D.V., Charney D.S., Murrough J.W. A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder. Biological Psychiatry 2014, 76:970-976.
64. Law A.J., Deakin J.F. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport 2001, 12:2971-2974.
65. Leach M.J., Baxter M.G., Critchley M.A.E. Neurochemical and behavioral aspects of lamotrigine. Epilepsia 1991, 32:S4-S8.
66. Li N., Lee B., Liu R.-J., Banasr M., Dwyer J.M., Iwata M., Li X.-Y., Aghajanian G., Duman R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
67. Liebrenz M., Stohler R., Borgeat A. Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression. World Journal of Biological Psychiatry 2009, 10:640-643.
68. Lindefors N., Barati S., O'Connor W.T. Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA in the rat medial prefrontal cortex. Brain Research 1997, 759:205-212.
69. Loo C.K., Katalinic N., Garfield J.B., Sainsbury K., Hadzi-Pavlovic D., Mac-Pherson R. Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial. Journal of Affective Disorders 2012, 142:233-240.
70. Luckenbaugh D.A., Niciu M.J., Ionescu D.F., Nolan N.M., Richards E.M., Brutsche N.E., Guevara S., Zarate C.A. Do the dissociative side effects of ketamine mediate its antidepressant effects?. Journal of Affective Disorders 2014, 159:56-61.
71. MacDonald J.F., Bartlett M.C., Mody I., Pahapill P., Reynolds J.N., Salter M.W., Schneiderman J.H., Pennefather P.S. Actions of ketamine, phencyclidine and MK-801 on NMDA receptor currents in cultured mouse hippocampal neurones. Journal of Physiology 1991, 432:483-508.
72. Machado-Vieira R., Salvadore G., DiazGranados N., Zarate C.A. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacology and Therapeutics 2009, 123:143-150.
73. Machado-Vieira R., Yuan P., Brutsche N., DiazGranados N., Luckenbaugh D., Manji H.K., Zarate C.A. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-d-aspartate antagonist. Journal of Clinical Psychiatry 2009, 70:1662-1666.
74. Maeng S., Zarate C.A., Du J., Schloesser R.J., McCammon J., Chen G., Manji H.K. Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biological Psychiatry 2008, 63:349-352.
75. Maes M., Verkerk R., Vandoolaeghe E., Lin A., Scharpe S. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatrica Scandinavica 1998, 97:302-308.
76. Mathew S.J., Murrough J.W., aan het Rot M., Collins K.A., Reich D.L., Charney D.S. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized placebo controlled continuation trial. International Journal of Neuropsychopharmacology 2010, 13:71-82.
77. Matrisciano F., Pannaccione A., Zusso M., Giusti P., Tatarelli R., Lacovelli L., Mathe A.A., Gruber S.H.M., Nicoletti F., Giradi P. Group-II metabotropic glutamate receptor ligands as adjunctive drugs in the treatment of depression: a new strategy to shorten latency of antidepressant medication?. Molecular Psychiatry 2007, 12:704-706.
78. Mayberg H.S., Lozano A.M., Voon V., McNeely H.E., Seminowicz D., Hamani C., Schwalb J.M., Kennedy S.H. Deep brain stimulation for treatment-resistant depression. Neuron 2005, 45:651-660.
79. McKie S., Del-Ben C., Elliot R., Williams S., del Vai N., Anderson I., Deakin J.F.W. Neuronal effects of acute citalopram detected by pharmacoMRI. Psychopharmacology 2005, 180:680-686.
80. Mealing G.A., Lanthorn T.H., Murray C.L., Small D.L., Morley P. Differences in degree of trapping of low-affinity uncompetitive N-methyl-d-aspartic acid receptor antagonists with similar kinetics of block. Journal of Pharmacology and Experimental Therapeutics 1999, 288:204-210.
81. Messer M., Haller I.V., Larson P., Pattison-Crisostomo J., Gessert C.E. The use of a series of ketamine infusions in two patients with treatment-resistant depression. Journal of Neuropsychiatry and Clinical Neuroscience 2010, 22:442-444.
82. Miguel-Hidalgo J.J., Waltzer R., Whittom A.A., Austin M.C., Rajkowska G., Stockmeier C.A. Glial and glutamatergic markers in depression, alcoholism and their comorbidity. Journal of Affective Disorders 2010, 127:230-240.
83. Mineur Y.S., Picciotto M.R., Sanacora G. Antidepressant-like effects of ceftriaxone in male C57BL/6J mice. Biological Psychiatry 2007, 61:250-252.
84. Moaddel R., Luckenbaugh D.A., Xie Y., Villasenor A., Brutsche N.E., Machado-Vieira R., Ramamoorthy A., Lorenzo M.P., Garcia A., Bernier M., Torjman M.C., Barbas C., Zarate C.A., Wainer I.W. d-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression. Psychopharmacology 2014, [Epub ahead of print]. 10.1007/s00213-014-3669-0.
85. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. Journal of Neuroscience 1997, 17:2921-2927.
86. Moryl E., Danysz W., Quack G. Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacology and Toxicology 1993, 72:394-397.
87. Mulrow C.D., Williams J.W., Chiquette E., Aguilar C., Hitchcock-Noel P., Lee S., Cornell J., Stamm K. Efficacy of newer medications for treating depression in primary care patients. American Journal of Medicine 2000, 108:54-64.
88. Murrough J.W., Iosifescu D.V., Chang L.C., Al Jurdi R.K., Green C.E., Perez A.M., Iqbal S., Pillemer S., Foulkes A., Shah A., Charney D.S., Mathew S.J. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. American Journal of Psychiatry 2013, 170:1134-1142.
89. Murrough J.W., Perez A.M., Pillemer S., Stern J., Parides M.K., aan het Rot M., Collins K.A., Mathew S.J., Charney D.S., Iosifescu D.V. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biological Psychiatry 2013, 74:250-256.
90. Narita M., Yoshizawa K., Nomura M., Aoki K., Suzuki T. Role of the NMDA receptor subunit in the expression of the discriminative stimulus effect induced by ketamine. European Journal of Pharmacology 2001, 423:41-46.
91. Nery F.G., Stanley J.A., Chen H.-H., Hatch J.P., Nicoletti M.A., Monkul E.S., Matsuo K., Caetano S.C., Peluso M.A., Najt P., Soares J.C. Normal metabolite levels in the dorsolateral prefrontal cortex of unmedicated major depressive disorder patients: a single voxel 1H spectroscopy study. Neuroimaging 2009, 174:177-183.
92. Niciu M.J., Luckenbaugh D.A., Ionescu D.F., Guevara S., Machado-Vieira R., Richards E.M., Brutsche N.E., Nolan N.M., Zarate C.A. Clinical predictors of ketamine response in treatment-resistant major depression. Journal of Clinical Psychiatry 2014, 75:e417-e423.
93. Nierenberg A.A., Fava M., Trivedi M.H., Wisniewski S.R., Thase M.E., McGrath P.J., Alpert J.E., Warden D., Luther J.F., Niederehe G. A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D report. American Journal of Psychiatry 2006, 163:1519-1530.
94. Nonaka S., Hough C.J., Chuang D.M. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-d-aspartate receptor-mediated calcium influx. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:2642-2647.
95. Nowak G., Legutko B., Skolnick P., Popik P. Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors. European Journal of Pharmacology 1998, 342:367-370.
96. Nowak G., Li Y., Paul I.A. Adaptation of cortical but not hippocampal NMDA receptors after chronic citalopram treatment. European Journal of Pharmacology 1996, 295:75-85.
97. Nudmamud-Thanoi S., Reynolds G.P. The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neuroscience Letters 2004, 372:173-177.
98. Okamoto N., Nakai T., Sakamoto K., Nagafusa Y., Higuchi T., Nishikawa T. Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia. Journal of ECT 2010, 26:223-227.
99. Pacher P., Kecskemeti V. Trends in the development of new antidepressants. Is there a light at the end of the tunnel?. Current Medicinal Chemistry 2004, 11:925-943.
100. Paslakis G., Gilles A., Meyer-Lindenberg A., Deuschle M. Oral administration of the NMDA receptor antagonists S-ketamine as add-on therapy of depression: a case series. Pharmacopsychiatry 2010, 43:33-35.
101. Paul R., Schaff N., Padberg F., Moller H.-J., Frodl T. Comparison of racemic ketamine and S-ketamine in treatment resistant major depression: report of two cases. World Journal of Biological Psychiatry 2009, 10:241-244.
102. Permoda-Osip A., Dorszewska J., Bartkowska-Sniatkowska A., Chlopocka-Wozniak M., Rybakowski J.K. Vitamin B12 level may be related to the efficacy of single ketamine infusion in bipolar depression. Pharmacopsychiatry 2013, 46:227-228.
103. Phelps L.E., Brutsche N., Moral J.R., Luckenbaugh D.A., Manji H.K., Zarate C.A. Family history of alcohol dependence and initial antidepressant response to an N-methyl-d-aspartate antagonist. Biological Psychiatry 2009, 65:181-184.
104. Pisani A., Bonsi P., Martella G., De Persis C., Costa C., Pisani F., Bernardi G., Calabresi P. Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine. Epilepsia 2004, 45:719-728.
105. Preskorn S.H., Baker B., Kolluri S., Menniti F.S., Krams M., Landen J.W. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment refractory major depressive disorder. Journal of Clinical Psychopharmacology 2008, 28:631-637.
106. Rasmussen K.G., Kung S., Lapid M.I., Oesterle T.S., Geske J.R., Nuttall G.A., Oliver W.C., Abenstein J.P. A randomized comparison of ketamine versus methohexital anesthesia in electroconvulsive therapy. Psychiatry Research 2014, 215:362-365.
107. Rasmussen K.G., Lineberry T.W., Galardy C.W., Kung S., Lapid M.I., Palmer B.A., Ritter M.J., Schak K.M., Sola C.L., Hanson A.J., Frye M.A. Serial infusions of low-dose ketamine for major depression. Journal of Psychopharmacology 2013, 27:444-450.
108. Reid J.G., Gitlin M.J., Altshuler L.L. Lamotrigine in psychiatric disorders. Journal of Clinical Psychiatry 2013, 74:675-684.
109. Reynolds I.J., Miller R.J. Tricyclic antidepressants block N-methyl-d-aspartate receptors: similarities to the action of zinc. British Journal of Pharmacology 1988, 95:95-102.
110. Rowland L.M., Bustillo J.R., Mullins P.G., Jung R.E., Lenroot R., Landgraf E., Barrow R., Yeo R., Lauriello J., Brooks W.M. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. American Journal of Psychiatry 2005, 162:394-396.
111. Salvadore G., Cornwell B.R., Colon-Rosario V., Coppola R., Grillon C., Zarate C.A., Manji H.K. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biological Psychiatry 2009, 65:289-295.
112. Salvadore G., Cornwell B.R., Sambataro F., Latov D., Colon-Rosario V., Carver F., Holroyd T., DiazGranados N., Machado-Vieira R., Grillon C., Drevets W.C., Zarate C.A. Anterior cingulate desynchonization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 2010, 35:1415-1422.
113. Salvadore G., van der Veen J.W., Zhang Y., Marenco S., Machado-Vieira R., Baumann J., Ibrahim L.A., Luckenbaugh D.A., Shen J., Drevets W.C., Zarate C.A. An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. International Journal of Neuropsychopharmacology 2012, 15:1063-1072.
114. Sanacora G., Banasr M. From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders. Biological Psychiatry 2013, 73:1172-1179.
115. Sanacora G., Kendell S.F., Levin Y., Simen A.A., Fenton L.R., Coric V., Krystal J.H. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biological Psychiatry 2007, 61:822-825.
116. Sancora G., Gueorguieva R., Epperson N., Wu Y.-T., Appel M., Rothman D.L., Krystal J.H., Mason G.F. Subtype-specific alterations of γ-aminobutyric acid and glutamate in patients with major depression. Archives of General Psychiatry 2004, 61:705-713.
117. Saricicek A., Maloney K., Muralidharan A., Ruf B., Blumberg H.P., Sanacora G., Lorberg B., Pittman B., Bhagwagar Z. Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 2011, 72:744-750.
118. Seeman P., Caruso C., Lasaga M. Memantine agonist action at dopamine D2 High receptors. Synapse 2008, 62:149-153.
119. Segmiller F., Ruther T., Linhardt A., Padberg F., Berger M., Pogarell O., Moller H.J., Kohler C., Schule C. Repeated S-ketamine infusions in therapy resistant depression: a case series. Journal of Clinical Pharmacology 2013, 53:996-998.
120. Sos P., Klirova M., Novak T., Kohutova B., Horacek J., Palenicek T. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. Neuroendocrinology Letters 2013, 34:287-293.
121. Southam E., Kirkby D., Higgins G.A., Hagan R.M. Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats. European Journal of Pharmacology 1998, 358:19-24.
122. Stefanczyk-Sapieha L., Oneschuk D., Demas M. Intravenous ketamine "burst" for refractory depression in a patient with advanced cancer. Journal of Palliative Medicine 2008, 11:1268-1271.
123. Szasz B.K., Mike A., Karoly R., Gerevich Z., Illes P., Vizi E.S., Kiss J.P. Direct inhibitory effect of fluoxetine on N-methyl-d-aspartate receptors in the central nervous system. Biological Psychiatry 2007, 62:1303-1309.
124. Szymkowicz S.M., Finnegan N., Dale R.M. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression. Journal of Affective Disorders 2013, 147:416-420.
125. Taylor M.J., Selvaraj S., Norbury R., Jezzard P., Cowen P.J. Normal glutamate but elevated myo-inositol in anterior cingulate cortex in recovered depressed patients. Journal of Affective Disorders 2009, 119:186-189.
126. Trivedi H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., Norquist G., Howland R.H., Lebowitz B., McGrath P.J., Shores-Wilson K., Biggs M., Balusubramani G.K., M F. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR·D: implications for clinical practice. American Journal of Psychiatry 2006, 163:28-40.
127. Trivedi M.H., Thase M.E., Fava M., Nelson C., Yang H., Qi Y., Tran Q.-H., Pikalov A., Carlson B.X., Marcus R.N., Berman R.M. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. Journal of Clinical Psychiatry 2008, 69:1928-1936.
128. Trullas R., Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. European Journal of Pharmacoology 1990, 185:1-10.
129. Vale S., Espejel M.A., Dominguez J.C. Amantadine in depression. Lancet 1971, II:437.
130. Valentine G.W., Mason G.F., Gomez R., Fasula M., Watzl J., Pittman B., Krystal J.H., Sanacora G. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS. Psychiatry Research 2011, 191:122-127.
131. Walker A.K., Budac D.P., Bisulco S., Lee A.W., Smith R.A., Beenders B., Kelley K.W., Dantzer R. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice. Neuropsychopharmacology 2013, 38:1609-1616.
132. Wang S.J., Wang K.Y., Wang W.C. Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience 2004, 125:191-201.
133. Wang X., Chen Y., Zhou X., Liu F., Zhang T., Zhang C. Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder. Journal of ECT 2012, 28:128-132.
134. Wieronska J.M., Legutko B., Dudys D., Pilc A. Olfactory bulbectomy and amitriptyline treatment influences mGlu receptors expression in the mouse brain hippocampus. Pharmacological Reports 2008, 60:844-855.
135. Williams S.R., Juszczak G., De-Groote C., Swiergiel A., Deakin W. Effects of acute serotonin elevation on brain glucose and neurotransmitter metabolism: a 13C MRS study in rats of citalopram administration. Proceedings of the International Society for Magnetic Resonance in Medicine 2007, 15:720.
136. Wong C.-S., Cherng C.-H., Luk H.-N., Ho S.-T., Tung C.-S. Effects of NMDA receptor antagonists on inhibition of morphine tolerance in rats: binding at μ-opioid receptors. European Journal of Pharmacology 1996, 297:27-33.
137. Yildiz-Yesiloglu A., Ankerst D.P. Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis. Psychiatry Research: Neuroimaging 2006, 147:1-25.
138. Yilmaz A., Schulz D., Aksoy A., Canbeyli R. Prolonged effect of an anaesthetic dose of ketamine on behavioral despair. Pharmacology Biochemistry and Behaviour 2002, 71:341-344.
139. Yoosefi A., Sepehri A.S., Kargar M., Akhondzadeh S., Sadeghi M., Rafei A., Alimadadi A., Ghaeli P. Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder: a randomized, double-blind study. Journal of ECT 2014, 30:15-21.
140. Zarate C.A., Brutsche N., Laje G., Luckenbaugh D.A., Venkata S.L., Ramamoorthy A., Moaddel R., Wainer I.W. Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biological Psychiatry 2012, 72:331-338.
141. Zarate C.A., Brutsche N.E., Ibrahim L., Franco-Chaves J., Diazgranados N., Cravchik A., Selter J., Marquardt C.A., Liberty V., Luckenbaugh D.A. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biological Psychiatry 2012, 71:939-946.
142. Zarate C.A., Mathews D.C., Furey M.L. Human biomarkers of rapid antidepressant effects. Biological Psychiatry 2013, 73:1142-1155.
143. Zarate C.A., Payne J.L., Quiroz J., Sporn J., Denicoff K.K., Luckenbaugh D., Charney D.S., Manji H.K. An open-label trial of riluzole in patients with treatment-resistant major depression. American Journal of Psychiatry 2004, 161:171-174.
144. Zarate C.A., Quiroz J.A., Singh J.B., Denicoff K.D., De Jesus G., Luckenbaugh D.A., Charney D.S., Manji H.K. An open-label trial of the glutamate modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biological Psychiatry 2005, 57:430-432.
145. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., Charney D.S., Manji H.K. A randomised trial of N-methyl-d-aspartate antagonist in treatment resistant major depression. Archives of General Psychiatry 2006, 63:856-864.
146. Zarate C.A., Singh J.B., Quiroz J., De Jesus G., Denicoff K.D., Luckenbaugh D.A., Manji H.K., Charney D.S. A double-blind placebo-controlled study of memantine in the treatment of major depression. American Journal of Psychiatry 2006, 163:153-155.
147. Zhang J.C., Li S.X., Hashimoto K. R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacology Biochemistry and Behavior 2014, 116:137-141.
148. Zhao X., Venkata S.L., Moaddel R., Luckenbaugh D.A., Brutsche N.E., Ibrahim L., Zarate C.A. Jr., Mager D.E, Wainer I.W. Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. British Journal of Clinical Pharmacology 2012, 74:304-314.
149. Zhou W., Wang N., Yang C., Li X.M., Zhou Z.Q., Yang J.J. Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. European Psychiatry 2014, 29:419-423.